New agents in relapsed/refractory Hodgkin's lymphoma☆

odgkin’s lymphoma (HL) is a B-cell malignancy that affects 000 new patients annually in the USA, representing approxmately 11% of all lymphomas.1 In the last decades, randomzed clinical trials conducted by cooperative groups in North merica and Europe have identified treatment schedules that rovide higher efficacy and lower toxicity with current treatent being expected to cure over 80% of patients.2 The threend five-year progression-free survival (PFS) rates range from 2% to 94%3–5 in patients with localized disease and from 71% o 86% in patients with advanced disease.6–14 Autologous stem cell transplantation (auto-SCT) has ecome the standard of care for relapsed or refractory HL.15,16 t leads to long-term PFS rates of approximately 50% in elapsed patients and of 30–40% in patients with primary efractory HL.6,15–20 The treatment of relapsed or refractory HL patients with reatment failure after an auto-SCT is a therapeutic challenge. isease relapse or progression after auto-SCT is associated ith a poor prognosis, with a median overall survival of 2.4 ears.21,22 While allogeneic stem cell transplantation (alloCT) represents the only potentially curative option, its role is till controversial.6,23,24 Data from retrospective and prospecive studies support the use of allo-SCT in particular settings. oreover, a recent analysis from the Center for International lood and Marrow Transplant Research (CIBMTR) reported ncouraging results with the use of reduced-intensity conitioning haploidentical transplantation, when compared to atched-unrelated donor transplantation.25 Briefly, when ecommending the procedure, other aspects should be taken nto account, such as age, the use of non-myeloablative